Loading…
Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker
BACKGROUND: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the potential diagnostic value of serum CD26 levels in gastric cancer. METHODS: S...
Main Authors: | , , , , , |
---|---|
Format: | Online Article Text |
Language: | English |
Published: |
BioMed Central
2015
|
Subjects: | |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608357/ https://www.ncbi.nlm.nih.gov/pubmed/26471376 http://dx.doi.org/10.1186/s12885-015-1757-0 |
_version_ | 1782395660688949248 |
---|---|
author | Boccardi, Virginia Marano, Luigi Rossetti, Rosaria Rita Amalia Rizzo, Maria Rosaria di Martino, Natale Paolisso, Giuseppe |
author_facet | Boccardi, Virginia Marano, Luigi Rossetti, Rosaria Rita Amalia Rizzo, Maria Rosaria di Martino, Natale Paolisso, Giuseppe |
author_sort | Boccardi, Virginia |
collection | PubMed |
description | BACKGROUND: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the potential diagnostic value of serum CD26 levels in gastric cancer. METHODS: Soluble serum CD26 levels were measured in pre and postoperative serum samples of 30 patients with gastric cancer and in 24 healthy donors by a specific ELISA kit. RESULTS: We found significantly lower serum CD26 levels in patients with gastric cancer (557.7 ± 118.3 pg/mL) compared with healthy donors (703.4 ± 170.3 pg/mL). Moreover patients with HER2 positive tumors had significantly lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006). A binary logistic model having gastric cancer as the dependent variable while age, gender, CEA, CA19.9 and CD26 levels as covariates, showed that CD26 serum levels were independently associated with gastric cancer presence. Indeed after 3 months from surgery serum CD26 levels significantly increased (700.1 ± 119.9 pg/mL vs 557.7 ± 118.3 pg/ml) in all patients (t = −4.454, p < 0.0001). CONCLUSIONS: This is a preliminary study showing that the measurement of serum CD26 levels could represent an early detection marker for gastric cancer. |
format | Online Article Text |
id | pubmed-4608357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46083572015-10-17 Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker Boccardi, Virginia Marano, Luigi Rossetti, Rosaria Rita Amalia Rizzo, Maria Rosaria di Martino, Natale Paolisso, Giuseppe BMC Cancer Research Article BACKGROUND: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types. Considering that serum CD26 levels have been previously associated with different cancers, we examined the potential diagnostic value of serum CD26 levels in gastric cancer. METHODS: Soluble serum CD26 levels were measured in pre and postoperative serum samples of 30 patients with gastric cancer and in 24 healthy donors by a specific ELISA kit. RESULTS: We found significantly lower serum CD26 levels in patients with gastric cancer (557.7 ± 118.3 pg/mL) compared with healthy donors (703.4 ± 170.3 pg/mL). Moreover patients with HER2 positive tumors had significantly lower CD26 serum levels (511.8 ± 84.8 pg/mL) compared with HER2 negative tumors (619.1 ± 109.9 pg/mL, p = 0.006). A binary logistic model having gastric cancer as the dependent variable while age, gender, CEA, CA19.9 and CD26 levels as covariates, showed that CD26 serum levels were independently associated with gastric cancer presence. Indeed after 3 months from surgery serum CD26 levels significantly increased (700.1 ± 119.9 pg/mL vs 557.7 ± 118.3 pg/ml) in all patients (t = −4.454, p < 0.0001). CONCLUSIONS: This is a preliminary study showing that the measurement of serum CD26 levels could represent an early detection marker for gastric cancer. BioMed Central 2015-10-15 /pmc/articles/PMC4608357/ /pubmed/26471376 http://dx.doi.org/10.1186/s12885-015-1757-0 Text en © Boccardi et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Boccardi, Virginia Marano, Luigi Rossetti, Rosaria Rita Amalia Rizzo, Maria Rosaria di Martino, Natale Paolisso, Giuseppe Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker |
title | Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker |
title_full | Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker |
title_fullStr | Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker |
title_full_unstemmed | Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker |
title_short | Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker |
title_sort | serum cd26 levels in patients with gastric cancer: a novel potential diagnostic marker |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608357/ https://www.ncbi.nlm.nih.gov/pubmed/26471376 http://dx.doi.org/10.1186/s12885-015-1757-0 |
work_keys_str_mv | AT boccardivirginia serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker AT maranoluigi serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker AT rossettirosariaritaamalia serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker AT rizzomariarosaria serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker AT dimartinonatale serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker AT paolissogiuseppe serumcd26levelsinpatientswithgastriccanceranovelpotentialdiagnosticmarker |